Molecular neuroimaging in degenerative dementias

Abstract

In the context of the limitations of structural imaging, brain perfusion and metabolism using SPECT and PET have provided relevant information for the study of cognitive decline. The introduction of the radiotracers for cerebral amyloid imaging has changed the diagnostic strategy regarding Alzheimer’s disease, which is currently considered to be a “continuum.” According to this new paradigm, the increasing amyloid loadwould be associated to the preclinical phase andmild cognitive impairment. It has been possible to observe “in vivo” images using C-PIB and PET scans. The characteristics of the C-PIB image include specific highbrain cortical area retention in thepositive cases with typical distribution pattern and no retention in the negative cases. This, in combination with F-FDG PET, is the basis of molecular neuroimaging as a biomarker. At present, its prognostic value is being evaluated in longitudinal studies. C-PIB-PET has become the reference radiotracer to evaluate the presence of cerebral amyloid. However, its availability is limited due to the need for a nearby cyclotron. Therefore, F labeled radiotracers are being introduced. Our experience in the last two years with CPIB, first in the research phase and then as being clinically applied, has shown the utility of the technique in the clinical field, either alone or in combination with FDG. Thus, amyloid image is a useful tool for the differential diagnosis of dementia and it is a potentially useful method for early diagnosis and evaluation of future treatments. © 2013 Elsevier España, S.L. and SEMNIM. All rights reserved. La neuroimagen molecular en las demencias degenerativas Palabras clave: C-PIB

9 Figures and Tables

Cite this paper

@inproceedings{Jimnez2017MolecularNI, title={Molecular neuroimaging in degenerative dementias}, author={Jaime F. Jim{\'e}nez and Carril Carril}, year={2017} }